{"id":55235,"date":"2026-01-23T06:11:37","date_gmt":"2026-01-22T22:11:37","guid":{"rendered":"https:\/\/flcube.com\/?p=55235"},"modified":"2026-01-23T06:11:38","modified_gmt":"2026-01-22T22:11:38","slug":"abbvie-secures-second-china-approval-for-risankizumab-in-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55235","title":{"rendered":"AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis"},"content":{"rendered":"\n

AbbVie Inc.<\/strong> (NYSE:\u202fABBV<\/a>) announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> has approved Risankizumab (SKYRIZI)<\/strong> for adult patients with moderately to severely active ulcerative colitis (UC)<\/strong> who have had an inadequate response, lost response, or were intolerant to conventional or biologic therapies. This marks the second major indication<\/strong> for risankizumab in China, following its approval for Crohn\u2019s disease last year.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>AbbVie Inc. (NYSE:\u202fABBV)<\/td><\/tr>
Drug<\/strong><\/td>Risankizumab (SKYRIZI)<\/td><\/tr>
Mechanism<\/strong><\/td>Interleukin\u201123 (IL\u201123) inhibitor<\/td><\/tr>
Approval<\/strong><\/td>NMPA (China) for ulcerative colitis<\/td><\/tr>
Patient Population<\/strong><\/td>Adults with moderately to severely active UC, refractory to conventional\/biologic therapies<\/td><\/tr>
Significance<\/strong><\/td>Second indication in China; first IL\u201123 inhibitor<\/strong> approved for UC globally<\/td><\/tr>
Previous Approval<\/strong><\/td>Crohn\u2019s disease (China, 2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Profile & Guideline Support<\/h2>\n\n\n\n